Abstract
Focal radiation necrosis of the brain (fRNB) is an adverse event (AE) following the treatment of benign or malignant brain lesions with stereotactic radiation therapy (SRT) or stereotactic radiosurgery (SRS). An increased incidence of fRNB has been reported in cancer patients (pts) treated with immune checkpoint inhibitors. Bevacizumab (BEV), a vascular endothelial growth factor-neutralizing monocolonal antibody, has shown to be an effective treatment for fRNB at a dose of 5-7.5 mg/kg Q2W x4. Based on pharmacokinetic/-dynamic data, a “low-dose regimen” of BEV (400 mg loading dose followed by 100 mg Q4W) was investigated in pts diagnosed with fRNB.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
